Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Collegium Pharmaceutical (COLL) over the last 6 years, with Q3 2025 value amounting to $11.9 million.

  • Collegium Pharmaceutical's Tax Provisions rose 9101.68% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 4314.6%. This contributed to the annual value of $56.2 million for FY2024, which is 8900.14% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Tax Provisions stood at $11.9 million, which was up 9101.68% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Tax Provisions peaked at $14.8 million during Q4 2023, and registered a low of -$61.9 million during Q2 2021.
  • Its 5-year average for Tax Provisions is -$216000.0, with a median of $991000.0 in 2021.
  • In the last 5 years, Collegium Pharmaceutical's Tax Provisions tumbled by 2524308.94% in 2021 and then surged by 690076.34% in 2024.
  • Over the past 5 years, Collegium Pharmaceutical's Tax Provisions (Quarter) stood at -$13.8 million in 2021, then soared by 95.72% to -$592000.0 in 2022, then soared by 2594.93% to $14.8 million in 2023, then tumbled by 67.96% to $4.7 million in 2024, then surged by 152.04% to $11.9 million in 2025.
  • Its Tax Provisions stands at $11.9 million for Q3 2025, versus $5.0 million for Q2 2025 and $705000.0 for Q1 2025.